Acadia Pharma (NASDAQ: ACAD) reported Q3 EPS of ($0.09), $0.17 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $131.6 million versus the consensus estimate of $127.75 million.

For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.